Pharmacological differences of glitazones: does peroxisome proliferator-activated receptor-alpha activation make the difference?

J Am Coll Cardiol. 2008 Sep 2;52(10):882-4. doi: 10.1016/j.jacc.2008.06.012. Epub 2008 Jul 9.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Endothelins / drug effects
  • Humans
  • Inflammation / drug therapy*
  • PPAR alpha / agonists*
  • PPAR gamma / agonists*
  • Pioglitazone
  • Rosiglitazone
  • Thiazolidinediones / pharmacology*
  • Thiazolidinediones / therapeutic use
  • Tumor Necrosis Factor-alpha / drug effects
  • Vascular Cell Adhesion Molecule-1 / drug effects

Substances

  • Endothelins
  • PPAR alpha
  • PPAR gamma
  • Thiazolidinediones
  • Tumor Necrosis Factor-alpha
  • Vascular Cell Adhesion Molecule-1
  • Rosiglitazone
  • Pioglitazone